Acrivon Therapeutics, Inc. (ACRV) Stock

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is led by CEO Peter Blume-Jensen, employs 75 people, headquartered in US, publicly traded since 2022.

Acrivon Therapeutics, Inc. (ACRV) stock trades at $1.73 with a market capitalization of $74.14M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.12, reflecting a net loss over the last twelve months, price-to-book of 1.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.27 and $3.56, and currently trades 51.4% below its 52-week high.

On profitability, Acrivon Therapeutics, Inc. generates a return on equity (ROE) of -70.14% (negative, reflecting a net loss), return on capital employed of -89.42%.

Acrivon Therapeutics, Inc. by the numbers, 2020–2025

Between 2020 and 2025 Acrivon Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-78.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-74.0M.

Borrowings stand at $3.0M, cash from operations was $-64.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -23.2% over five years, and was -69.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Acrivon Therapeutics, Inc. (ACRV) — frequently asked questions